Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...
ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback